Brendan Smith's most recent trade in CRISPR Therapeutics AG was a trade of 3,825 Restricted Stock Units done . Disclosure was reported to the exchange on Feb. 18, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| CRISPR Therapeutics AG | Brendan Smith | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2023 | 3,825 | 11,475 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Brendan Smith | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2023 | 3,825 | 6,464 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Brendan Smith | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 48.26 per share. | 18 Feb 2023 | 1,392 | 5,072 (0%) | 0% | 48.3 | 67,178 | Common Shares |
| CRISPR Therapeutics AG | Brendan Smith | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Oct 2022 | 3,750 | 11,250 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Brendan Smith | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Oct 2022 | 3,750 | 3,750 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | Brendan Smith | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 55.76 per share. | 14 Oct 2022 | 1,111 | 2,639 (0%) | 0% | 55.8 | 61,949 | Common Shares |
| CRISPR Therapeutics AG | Brendan Smith | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2022 | 14,000 | 14,000 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Brendan Smith | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2022 | 10,000 | 10,000 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Brendan Smith | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2022 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Brendan Smith | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2022 | 15,300 | 15,300 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | Brendan Smith | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Oct 2021 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Brendan Smith | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Oct 2021 | 15,000 | 15,000 | - | - | Restricted Stock Units |